The capital raise supports ongoing Phase 2b/3 clinical trial for prevention of bronchopulmonary dysplasia and associated CMC and analytical activities

此次融资将支持正在进行的预防支气管肺发育不良的2b/3期临床试验，以及相关的化学、制造和控制（CMC）和分析活动。

Approximately 94% of existing investors participated in the Series E-2 round

约94%的现有投资者参与了E-2轮融资

Interim analysis completing the Phase 2b portion of the trial expected by the end of Q2 2027

预计于2027年第二季度末完成试验的2b期部分的中期分析

ATLANTA

亚特兰大

,

，

Aug. 25, 2026

2026年8月25日

/PRNewswire/ --

/美通社/ --

Airway Therapeutics, Inc.

气道治疗公司

, a late-stage clinical biopharmaceutical company developing novel biologic therapies for respiratory, inflammatory, and infectious diseases, today announced the closing of a $50 million equity round to support the continued late-stage clinical development of zelpultide alfa, the Company's novel recombinant human surfactant protein D (rhSP-D)..

，一家致力于开发针对呼吸系统、炎症性和感染性疾病的新型生物疗法的后期临床阶段生物制药公司，今日宣布完成一轮5,000万美元的股权融资，以支持其新型重组人表面活性蛋白D（rhSP-D）——zelpultide alfa的持续后期临床开发。

The E-round consists of $26 million previously raised through a SAFE financing and $24 million through the Company's Series E-2 round. Proceeds will primarily support Airway's completion of the ongoing Phase 2b portion of the Phase 2b/3 clinical trial evaluating zelpultide alfa for the prevention of bronchopulmonary dysplasia (BPD) in very preterm infants, as well as associated chemistry, manufacturing and controls (CMC) and analytical activities required to advance the program..

E轮融资包括此前通过简单未来股权协议（SAFE）融资筹集的2,600万美元，以及通过公司E-2轮系列融资筹集的2,400万美元。所得资金将主要用于支持Airway完成正在进行的2b/3期临床试验中2b阶段部分，该试验旨在评估zelpultide alfa在预防极早产儿支气管肺发育不良（BPD）方面的疗效；同时还将支持与推进该项目相关的化学、生产和控制（CMC）及分析活动。

The Series E-2 round received broad participation from Airway's existing investor base, with approximately 94% of existing investors participating in the round. Participants included Cincinnati Children's and a syndicate of large family offices, who are committed to advancing novel therapies for serious respiratory diseases..

E-2轮融资获得了Airway现有投资者群体的广泛参与，约94%的现有投资者参与了本轮融资。参与者包括辛辛那提儿童医院以及一个由大型家族办公室组成的银团，他们致力于推动针对严重呼吸系统疾病的创新疗法的发展。

'We are extremely pleased by the strong participation and continued support of our existing investors, with approximately 94% of our current cap table participating in the Series E-2 round, reflecting their confidence in Airway, our team and the potential of zelpultide alfa,' said Marc Salzberg, MD, Chairman and Chief Executive Officer of Airway Therapeutics.

“我们对现有投资者的强烈参与和持续支持感到非常高兴，目前资本结构中约94%的投资者参与了E-2轮融资，这反映了他们对Airway Therapeutics、我们的团队以及zelpultide alfa潜力的信心。”Airway Therapeutics董事长兼首席执行官Marc Salzberg医学博士表示。

'With this round, we are well positioned to maintain momentum across our late-stage clinical program as we evaluate zelpultide alfa for the prevention of BPD in very preterm infants, a population with significant unmet medical need and no approved preventive therapies.'.

“通过本轮融资，我们有充分的能力在后期临床项目中保持势头，评估zelpultide alfa在极早产儿中预防支气管肺发育不良（BPD）的效果，这一人群存在巨大的未满足医疗需求，且目前尚无获批的预防性疗法。”

'This round further solidifies Airway's financial position as we execute the ongoing Phase 2b/3 clinical trial and prepare for the program's next important development milestones,' said Alan S. Wolk, MBA, Chief Financial Officer and Chief Operating Officer of Airway Therapeutics

“本轮融资进一步巩固了Airway Therapeutics的财务地位，我们正在推进正在进行的2b/3期临床试验，并为该项目的下一个重要开发里程碑做好准备。” Airway Therapeutics首席财务官兼首席运营官Alan S. Wolk工商管理硕士表示。

.

。

'The proceeds provide us with the capital to support the clinical study as well as the CMC and BLA readiness analytical work necessary to advance zelpultide alfa through late-stage development in a disciplined and efficient manner.'

所得款项为我们提供了资金，以支持临床研究，以及推进zelpultide alfa在后期开发中所需的CMC和BLA准备分析工作，确保其以规范且高效的方式进行。

Airway's next major development milestone is the planned interim analysis marking the completion of the Phase 2b portion of the ongoing Phase 2b/3 clinical trial. Results from the interim analysis are expected by the end of the second quarter of 2027.

Airway的下一个重大开发里程碑是计划中的中期分析，标志着正在进行的2b/3期临床试验中2b期部分的完成。预计中期分析的结果将在2027年第二季度末公布。

About Zelpultide Alfa

关于泽尔普肽阿尔法

Zelpultide alfa is a recombinant human surfactant protein D (rhSP-D) precisely engineered to replicate the native protein's full quaternary structure and biological function, incorporating optimized glycosylation through advanced cell line technology. Its therapeutic activity is driven by three key mechanisms: modulation of immune responses to mitigate excessive inflammation, enhancement of pathogen recognition and clearance, and maintenance of surfactant homeostasis to support pulmonary function.

Zelpultide alfa 是一种重组人表面活性蛋白 D（rhSP-D），通过先进的细胞系技术引入优化的糖基化，经过精密工程设计以复刻天然蛋白的完整四级结构和生物功能。其治疗活性由三大关键机制驱动：调节免疫反应以减轻过度炎症、增强病原体的识别与清除，以及维持表面活性物质稳态以支持肺功能。

As a versatile biologic platform, zelpultide alfa is being developed for patients across all age groups—from preventing bronchopulmonary dysplasia (BPD) in very preterm infants to treating acute and chronic respiratory, inflammatory and infectious conditions in adults..

作为一种多功能生物制剂平台，zelpultide alfa 正在为所有年龄段的患者开发，从预防极早产儿的支气管肺发育不良（BPD），到治疗成人的急性和慢性呼吸系统、炎症和感染性疾病。

Zelpultide alfa's lead indication, BPD prevention, is currently progressing through a Phase 2b/3 clinical trial, following a Phase 1b study that demonstrated a favorable safety and tolerability profile.

Zelpultide alfa 的首要适应症（预防支气管肺发育不良）目前正处于 IIb/III 期临床试验阶段，此前的一项 Ib 期研究已证实其具有良好的安全性和耐受性。

About Airway Therapeutics

关于Airway Therapeutics

Airway Therapeutics is a late-stage clinical biopharmaceutical company developing a new class of biologic therapies to redefine the prevention and treatment of respiratory, inflammatory, and infectious diseases. Its lead candidate, zelpultide alfa, is currently in late-stage clinical development for the prevention of bronchopulmonary dysplasia (BPD) in very preterm infants, a condition with no approved preventive therapies.

Airway Therapeutics 是一家处于后期临床阶段的生物制药公司，正在开发一类新型生物疗法，以重新定义呼吸系统疾病、炎症性疾病和感染性疾病的预防与治疗。其核心候选药物 zelpultide alfa 目前正处于后期临床开发阶段，用于预防极早产儿的支气管肺发育不良（BPD），而该病症尚无获批的预防性疗法。

As a platform biologic, zelpultide alfa is also being advanced for broader application across age groups and disease settings, with the goal of improving outcomes for vulnerable patient populations..

作为一种平台化生物药，zelpultide alfa 也在推进更广泛的应用，涵盖不同年龄组和疾病场景，旨在改善脆弱患者群体的预后。

For more information, please visit

更多信息，请访问

https://www.airwaytherapeutics.com

https://www.airwaytherapeutics.com

Company Contact:

公司联系人：

Libba Muzi

利巴·穆齐

Airway Therapeutics

气道治疗公司

[email protected]

[email protected]

513-770-9630

513-770-9630

SOURCE Airway Therapeutics

来源：Airway Therapeutics

21

二十一

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

申请演示